Biocon Eyes Strong Q3 Driven by Biosimilar Surge

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Biocon Eyes Strong Q3 Driven by Biosimilar Surge
Overview

Biocon is poised for a robust Q3FY26, with biosimilars set to lead the charge. Analysts project substantial revenue growth driven by key products like bStelara and emerging market traction. The generics segment also shows promise with new launches, though competition looms. This marks the first results post-BBL consolidation, with topline expected to surge 18%.

Biosimilar Momentum

This quarter will provide the first consolidated view of Biocon Biologics Ltd (BBL) following its integration, with overall topline expected to rise a significant 18%. Core biosimilar sales are forecast to reach $315 million, marking a robust 23% year-on-year increase. This surge is attributed to market share gains across key products, including the ongoing ramp-up of bStelara in the crucial United States market and improving traction in emerging markets.

Generics Segment Outlook

In the generics division, Kotak Institutional Equities estimates a 17% year-on-year growth. This is largely supported by the continued benefits from the Liraglutide launch in the United Kingdom and European markets. Syngene, the contract research arm, is projected to see a more modest 4% year-on-year revenue increase.

Divergent Brokerage Views

While many anticipate strong results, Axis Securities offers a more tempered perspective. They forecast 7% YoY growth in the research segment and anticipate pressure on the generics business due to intensifying competition. However, Axis Securities also projects biosimilar revenue to grow around 18% year-on-year, buoyed by new launches such as Insulin Aspart, Yesafili, Denosumab biosimilars, and Liraglutide in the UK.

Margin Improvements

Gross margins for the biosimilars business are expected to see a healthy 100 basis point quarter-on-quarter improvement, reaching 65%. Consequently, EBITDA for the biosimilars segment is projected to climb 31% year-on-year to ₹980 crore. Investors will be keenly observing management commentary regarding the integration of BBL and the strategic outlook for future product pipelines.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.